Insilico, a biotech firm, showcases a new AI-driven drug discovery for lung diseases amidst its third Hong Kong IPO attempt. Founded in 2014 at Johns Hopkins University, Insilico is now based in Boston, with operations in mainland China and Hong Kong. With a lab in Suzhou and an office at Science Park, the company is making significant strides in the biotech industry.
This latest development in AI-driven drug discovery for lung diseases not only highlights Insilico’s innovative approach but also underscores the growing importance of artificial intelligence in biotech research. The firm’s expansion to different regions indicates a strategic move to capitalize on various markets. As biotech continues to evolve, with Boston being a key hub, Insilico’s advancements pave the way for potential breakthroughs in treating respiratory conditions, benefiting both patients and the biotech industry as a whole.
Read more about it from scmp.com
